Cantargia AB
The answer first
Does Cantargia beat the market?
No, Cantargia has not beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 78% of Nordic stocks
- Quality96
- Value94
- Trend3
No. 28 of 195 in healthcare
Expectations in the price
Low expectations
For the share to return about 9% a year from today's price, it is enough that the cash Cantargia keeps shrinks about 31% a year for 10 years.
Max for seven days
Follow Cantargia with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about Cantargia
Your first answer is free, no account needed.
Do you own Cantargia, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Cantargia and a few more. Free, no card.
Super Stock+44.6%In short
- Cantargia has fallen 62.7% over the past year, including dividends.
- Overall, Cantargia ranks better than 78% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 94.1%. The price is 97.8% below its peak now.
What do analysts think of Cantargia?
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 78% of Nordic stocks.
No. 28 of 195 in healthcare
High A solid company: it earns well on its money and has healthy finances.
No. 16 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity0.00
- Asset turnoverSales divided by everything the company owns1.03
- Return on equityProfit divided by equity+63.4%
- Cash conversionOperating cash flow divided by profit0.98
The ranking is built on equity ratio, ROA and how steadily profit grows.
High Low price: you pay little for what the company earns and owns.
No. 7 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50
- P/BPrice divided by equity1.2
- P/SPrice divided by sales1.0
- P/EPrice divided by earnings1.8
- P/CFPrice divided by operating cash flow1.8
The ranking is built on P/E, P/B and P/S.
Low Headwind in the share price: it has done worse than most over the last year.
No. 183 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months−38.7%
- 6 months−57.9%
- 9 months−74.7%
- 12 months−62.7%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
The funds that own Cantargia
5 funds we follow own Cantargia. The share is how much of the fund the stock makes up.
- Sweden5
From the funds' latest known holdings.
About Cantargia
Cantargia AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 22 employees.
Cantargia AB (publ), a biotechnology company, develops pharmaceuticals for treatment of cancer, inflammatory, and autoimmune diseases. The company is developing CAN04 (nadunolimab), an monoclonal antibody that can bind IL1RAP, which is in phase II clinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer; and CAN10, an antibody against IL1RAP, which is in phase 1 clinical trial for the treatment of autoimmune and inflammatory diseases, including systemic sclerosis and myocarditis. It also develops CANxx, an IL1RAP-based antibody platform.


See the full analysis of Cantargia.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card